New Cousteau-Linked...
Health Care: Drugs
ADVENTRX Pharmaceuticals Inc. (ANX: AMEX)
$0.51 -0.01 | -2.11%
06/04/12 - 03:14 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.19 | 0.58 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.47 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 0.57 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -1.70 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -1.50 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 23.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 24.30 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -5,710.77 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -25.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -56.60 | 2.20 | 2.50 |
| Return on Investment (TTM) | -27.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -64.30 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -111,200.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 0.00 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with ANX
- Portfolio NameUser Type
- Uservlady 1
- Usertesting
- Contributor5 Stocks Under-$10 Setting ...
- ContributorBreakout Stocks Of The Week...
- ContributorHot Biotech Trades for Seco...
- UserDusty's Tracker
- UserDustel's Growth Stocks
- UserOwn
- UserASCO 2010 Part 2
- UserCDBrevard Portfolio 1
Latest ANX Headlines from TheStreet
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- ADVENTRX Stock Gaps Down On Today's Open (ANX) 11.11.11 | 08:11 am
- 5 Stocks Under $10 Setting Up to Trade Higher 09.15.11 | 01:09 pm
- 5 Stocks Setting Up to Break Out 09.09.11 | 03:09 pm
- ADVENTRX Stock Hits New 52-Week Low (ANX) 08.10.11 | 09:08 am
- Adventrx: FDA Rejects Lung Cancer Drug 08.10.11 | 07:08 am
- ADVENTRX Stock Gaps Down On Today's Open (ANX) 08.08.11 | 10:08 am
- Biotech Stock Mailbag: Sangamo Biosciences 07.22.11 | 05:07 am
- Biotech Stock Live Chat 07.15.11 | 12:07 pm
- Biotech Stock Mailbag: Adventrx Pharma 07.15.11 | 05:07 am
Press Releases for ANX
- ADVENTRX Pharmaceuticals To Sponsor & Present At The Martin Center's 2012 Sickle Cell Disease Conference - PR Newswire 04.16.12 | 08:04 am
- ADVENTRX Announces Establishment Of Regulatory Advisory Board - PR Newswire 04.09.12 | 08:04 am
- Vista Partners Updates Coverage On ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price - PR Newswire 03.21.12 | 09:03 am
- ADVENTRX CEO Selected By Combined Health Agencies As A 2012 Health Hero - PR Newswire 03.15.12 | 08:03 am
- ADVENTRX Pharmaceuticals To Present At The 14th Annual BIO CEO & Investor Conference On February 14 - PR Newswire 02.07.12 | 08:02 am
- Vista Partners Publishes February 2012 Newsletter - PR Newswire 02.02.12 | 09:02 am
- Vista Partners Updates Coverage On ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price - PR Newswire 12.15.11 | 09:12 am
- ADVENTRX Meets With FDA To Discuss Development Plans For ANX-188 - PR Newswire 12.01.11 | 08:12 am
- ADVENTRX Announces Closing Of Public Offering - PR Newswire 11.16.11 | 03:11 pm
- ADVENTRX Prices Public Offering Of Stock - PR Newswire 11.11.11 | 08:11 am
Partner Headlines for ANX
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 12.19.11 | 09:12 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- Blue Horseshoe - Or Someone - Likes Anaconda Mining; Shares Pop 20% After Selling Iron Ore Assets - NASDAQ 12.07.11 | 06:12 pm
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 12.02.11 | 09:12 am
- 5 Healthcare Stocks To Consider - Seeking Alpha 09.01.11 | 08:09 am
- Company News for August 11, 2011 - Corporate Summary - Zacks 08.11.11 | 10:08 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 08.10.11 | 09:08 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 07.21.11 | 09:07 am
- Adventrx Pharmaceuticals: Undervalued Based on Product Approval Potential - Seeking Alpha 07.21.11 | 08:07 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
